SCHEMBL22085181

SCHEMBL22085181

CC(=O)Nc1nc2ccc(B3OC(C)(C)C(C)(C)O3)cc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.52
RAF1 P04049 3/20 0.41
TUBB4A P04350 3/20 0.41
TUBB P07437 3/20 0.41
TUBA3C P0DPH7 3/20 0.41
TUBA1B P68363 3/20 0.41
TUBA4A P68366 3/20 0.41
TUBB4B P68371 3/20 0.41
TUBB3 Q13509 3/20 0.41
TUBB2A Q13885 3/20 0.41
TUBB8 Q3ZCM7 3/20 0.41
TUBA3E Q6PEY2 3/20 0.41
TUBA1A Q71U36 3/20 0.41
TUBA1C Q9BQE3 3/20 0.41
TUBB6 Q9BUF5 3/20 0.41
TUBB2B Q9BVA1 3/20 0.41
TUBB1 Q9H4B7 3/20 0.41
CYP1A2 P05177 5/20 0.40
HIF1A Q16665 5/20 0.40
ABL1 P00519 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23926180 0.90 LMNA (0.52) LMNARAF1HIF1AALDH1A1SMN1; SMN2
SCHEMBL3301830 0.83 LPL (0.38) LMNARAF1HIF1ASMN1; SMN2HTT
SCHEMBL3759602 0.78 RIPK1 (0.53) LMNARAF1HIF1ASMN1; SMN2HTT
SCHEMBL15574354 0.76 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL3831957 0.75 PLAU (0.47) ABL1ALDH1A1MEN1KMT2A
SCHEMBL15296449 0.75 EGFR (0.40) ALDH1A1SMN1; SMN2HPGD
SCHEMBL8029056 0.74 TUBB4A (0.67) LMNARAF1TUBB4ATUBBTUBA3C
SCHEMBL7892505 0.74 PIK3CA (0.44) LMNAHIF1AABL1ALDH1A1SMN1; SMN2
SCHEMBL28799612 0.73 LMNA (0.63) LMNARAF1TUBB4ATUBBTUBA3C
SCHEMBL799198 0.73 DYRK1A (0.59) CYP1A2ALDH1A1CYP2C9SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3475285-B1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF SUZHOU KINTOR PHARMACEUTICALS INC (CN) 2022-02-09 EP disclosed
US-11242346-B2 Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2022-02-08 US disclosed
US-20200181147-A1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2020-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242346-B2 Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof MTOR, RPTOR, RICTOR LMNA 3865/4885RAF1 184/4885TUBB4A 3592/4885
US-20200181147-A1 MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF MTOR, RPTOR, RICTOR LMNA 3865/4885RAF1 184/4885TUBB4A 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.